SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Parmax Pharma - Quaterly Results

14 Feb 2024 Evaluate
The Sales for the quarter ended December 2023 of Rs. 13.27 million declined by -75.21% from Rs. 53.53 millions.The Net Loss for the quarter ended December 2023 is Rs. -17.53 millions as compared to Net Profit of Rs. 17.44 millions of corresponding quarter ended December 2022Operating profit Margin for the quarter ended December 2023 slipped to -11.43% as compared to 23.28% of corresponding quarter ended December 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 13.27 53.53 -75.21 67.95 90.42 -24.85 154.24 182.51 -15.49
Other Income 0.11 0.09 22.22 0.34 0.25 36.00 0.40 0.63 -36.51
PBIDT -11.43 23.28 -149.10 -25.36 14.45 -275.50 22.93 26.21 -12.51
Interest 1.56 1.06 47.17 4.59 3.14 46.18 3.69 3.86 -4.40
PBDT -12.99 22.22 -158.46 -29.95 11.31 -364.81 19.24 22.35 -13.91
Depreciation 4.54 4.78 -5.02 13.05 14.06 -7.18 18.79 19.32 -2.74
PBT -17.53 17.44 -200.52 -43.00 -2.75 1463.64 0.45 3.03 -85.15
TAX 0.00 0.00 0.00 0.00 0.00 0.00 1.50 1.62 -7.41
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 -0.35 -0.63 -44.44
PAT -17.53 17.44 -200.52 -43.00 -2.75 1463.64 -1.05 1.41 -174.47
Equity 37.41 37.41 0.00 37.41 37.41 0.00 37.41 37.41 0.00
PBIDTM(%) -86.13 43.49 -298.06 -37.32 15.98 -333.54 14.87 14.36 3.52

Parmax Pharma Share Price

32.99 1.29 (4.07%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×